Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

References

• JemalASiegelRXuJWardECancer Statistics 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• AlgireGHChalkleyHWLegallaisFYVascular reactions of normal and malignant tissue in vivo. Vascular reactions of mice to wound and to normal and neoplastic transplantsJ Natl Cancer Inst194567385
   Web of Science ®Google Scholar
• CaoYTanAGaoFLiuLLiaoCMoZA meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancerInt J Colorectal Dis20092467768519184059
   PubMed Web of Science ®Google Scholar
• WelchSSpithoffKRumbleBMarounJGastrointestinal Cancer Disease Site GroupBevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systemic reviewAnn Oncol2010211152116219942597
   PubMed Web of Science ®Google Scholar
• FerraraNMolecular and biological properties of vascular endothelial growth factorJ Mol Med19997752754310494799
   PubMed Web of Science ®Google Scholar
• McMahonGVEGF receptor signaling in tumor angiogenesisOncologist2000531010804084
   PubMedGoogle Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res199757459345999377574
   PubMed Web of Science ®Google Scholar
• GordonMSMargolinKTalpazMPhase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancerJ Clin Oncol20011984385011157038
   PubMed Web of Science ®Google Scholar
• MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol2010283239324720498403
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with MCRCJ Clin Oncol200321606512506171
   PubMed Web of Science ®Google Scholar
• KabbinavarFFSchulzJMcCleodMAddition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trialJ Clin Oncol2005233697370415738537
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovontnyWBevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJNealJEastern Cooperative Oncology Group Study E3200Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2007251539154417442997
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
   PubMed Web of Science ®Google Scholar
• GruenbergerBTamandlDSchuellerJBevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancerJ Clin Oncol2008261830183518398148
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesis: past, present and the near futureCarcinogenesis20002150551510688871
   PubMed Web of Science ®Google Scholar
• AsaharaTTakahashiTMasudaHVEGF contributes to postnatal neovascularization by mobilizing bone marrow derived endothelial progenitor cellsEMBO J1999183964397210406801
   PubMed Web of Science ®Google Scholar
• LydenDHattoriKDiasSImpaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cell blocks tumor angiogenesis and growthNat Med200171194120111689883
   PubMed Web of Science ®Google Scholar
• BalukPHashizumeHMcDonaldDMCellular abnormalities of blood vessels as targets in cancerCurr Opin Genet Dev20051510211115661540
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature200040724925711001068
   PubMed Web of Science ®Google Scholar
• VerheulHMVoestEESchlingmannROAre tumors angiogenesis dependent?J Pathol200420251314694516
   PubMed Web of Science ®Google Scholar
• HashizumeHBalukPMorikawaSOpenings between defective endothelial cells explain tumor vessel leakinessAm J Pathol20001561363138010751361
   PubMed Web of Science ®Google Scholar
• PaderaTPStollBRTooredmanJBPathology: cancer cells compress intratumor vesselsNature2004427Abstract 695
   Web of Science ®Google Scholar
• CoussensLMWerbZInflammation and cancerNature200242086086712490959
   PubMed Web of Science ®Google Scholar
• FerraraNDavis-SmythTThe biology of vascular endothelial growth factorEndocr Rev1997184259034784
   PubMed Web of Science ®Google Scholar
• PlouëtJSchillingJGospodarowiczDIsolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cellsEMBO J19898380138062684646
   PubMed Web of Science ®Google Scholar
• DvorakHFVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin Oncol2002204368438012409337
   PubMed Web of Science ®Google Scholar
• MelderRJKoeningGCWitwerBPSafabakhshNMunnLLJainRKDuring angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endotheliumNat Med199629929978782456
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev20042558161115294883
   PubMed Web of Science ®Google Scholar
• MacedoLTLimaASasseADAddition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroupsBMC Cancer2012128922414244
   PubMed Web of Science ®Google Scholar
• StathopoulosGPBatziouCTrafalisDTreatment of colorectal cancer with and without bevacizumab: a Phase III studyOncology20107837638120798560
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first line treatment of metastatic colorectal cancer: results from the BICC-C studyJ Clin Oncol2007254779478617947725
   PubMed Web of Science ®Google Scholar
• SobreroAAcklandSClarkSAVIRI Trial investigatorsPhase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancerOncology20097711311919628950
   PubMed Web of Science ®Google Scholar
• KopetzSHoffPMMorrisJSAVIRI Trial investigatorsPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenetic biomarkers associated with therapeutic resistanceJ Clin Oncol20102845345920008624
   PubMed Web of Science ®Google Scholar
• GoldbergRMSargentDJMortonRFA randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200422233014665611
   PubMed Web of Science ®Google Scholar
• HochsterHSHartLLRamanathanRKSafety and efficacy of oxaliplatin and fluoropyrimidines regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. Results of the TREE StudyJ Clin Oncol2008263523352918640933
   PubMed Web of Science ®Google Scholar
• TebbuttNCWilsonKGebskiVJCapecitabine, bevacizumab and mitomycin in first line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized Phase III MAX studyJ Clin Oncol2010283191319820516443
   PubMed Web of Science ®Google Scholar
• CohenMHGootenbergJKeeganPPazdurRFDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerOncologist20071235636117405901
   PubMed Web of Science ®Google Scholar
• MorikawiTBandoHTakashimaABevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Med Oncol12312011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• YildizRBuyukberberSUnerABevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimensCancer Invest201028333719995229
   PubMed Web of Science ®Google Scholar
• HoritaYYamadaYKatoKPhase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trialInt J Clin Oncol10152011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• MishimaHObaKSakamotoJFOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized Phase III Study (EAGLE Study)Jpn J Clin Oncol20124213413822167662
   PubMed Web of Science ®Google Scholar
• BennounaJBorgCDelordJPBevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyClin Colorectal Cancer201211384421803002
   PubMed Web of Science ®Google Scholar
• ChenHXMooneyMBoronMPhase II multicenter trial of bevacizumab plus fluoropyrimidines and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301J Clin Oncol2006243354336016849749
   PubMed Web of Science ®Google Scholar
• ParkLCLeeHSShinSHBevacizumab as a second- or later-line of treatment for metastatic colorectal cancerWorld J Gastroenterol2012181104110922416186
   PubMed Web of Science ®Google Scholar
• LievreASamalinEMitryEBevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyBMC Cancer2009934719785749
   PubMed Web of Science ®Google Scholar
• KangBWKimTWLeeJLBevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysisMed Oncol200926323718498064
   PubMed Web of Science ®Google Scholar
• KwonHCOhSYLeeSKimSHKimHJBevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot studyWorld J Gastroenterol2007136231623518069765
   PubMed Web of Science ®Google Scholar
• Van CutsemERiveraFBerrySFirst BEAT InvestigatorsSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol2009201842184719406901
   PubMed Web of Science ®Google Scholar
• BouganimNKavanMEidMMetrakosPChaudhuryPBatistGPerioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot studyJ Clin Oncol20092715S Supple15027
   Google Scholar
• BlazerDG3rdKishiYMaruDMPathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesJ Clin Oncol2008265344535118936472
   PubMed Web of Science ®Google Scholar
• MasiGLoupakisFSalvatoreLBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialLancet Oncol20101184585220702138
   PubMed Web of Science ®Google Scholar
• WongRCunninghamDBarbachanoYA multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for up-front resectionAnn Oncol2011222042204821285134
   PubMed Web of Science ®Google Scholar
• OkinesAPuertoODCunninghamDSurgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and randomized Phase-III NO16966 trialBr J Cancer20091011033103819789532
   PubMed Web of Science ®Google Scholar
• RiberoDWangHDonadonMBevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastasesCancer20071102761276717960603
   PubMed Web of Science ®Google Scholar
• KlingerMTamandlDEipeldauerSBevacizumab improves pathologic response of colorectal cancer liver metastases treated with XELOX/FOLFOXAnn Surg Oncol2010172059206520177795
   PubMed Web of Science ®Google Scholar
• ChibaudelBTournigandCAndréTDe GramontATherapeutic strategy in unresectable metastatic colorectal cancerTher Adv Med Oncol20124758922423266
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol2008265326533418854571
   PubMed Web of Science ®Google Scholar
• AndreTVieitezJMBoucheOBevacizumab plus chemotherapy beyond first progression in metastatic colorectal cancer patients previously treated with bevacizumab-based therapy: TML study subgroup findingsAnn Oncol201223Suppl 4Abstract O-0020
   Google Scholar
• Van CutsemEVieitezJMBoucheORandomised phase III study of bevacizumab plus chemotherapy beyond progression in bevacizumab-treated patients with metastatic colorectal cancer: TML study KRAS subgroup findingsAnn Oncol201223Suppl 4Abstract O-0021
   Google Scholar
• GrotheyAHartLRowlandKIntermittent oxaliplatin administration improves time to-treatment failure in metastatic colorectal cancer: final results of the Phase III of the CONcePT TrialJ Clin Oncol200826SupplAbstract 4010
   Google Scholar
• Díaz-RubioEGómez-EspañaAMassutíBSpanish Cooperative Group for the Treatment of Digestive TumorsFirst-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the Phase III MACRO TTD studyOncologist201217152522234633
   PubMed Web of Science ®Google Scholar
• TournigandCSamsonBScheithauerWBevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM Phase III trialJ Clin Oncol201230SupplAbstract LBA3500
   Google Scholar
• JohnssonAFrodinJBerglundAA randomized phase III trial on maintenance treatment with Bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)J Clin Oncol201129Supplabstract 3526
   Web of Science ®Google Scholar
• InceWLJubbAMHoldenSNAssociation of k-ras, b-raf and p-53 status with the treatment effect of bevacizumabJ Natl Cancer Inst20059798198915998951
   PubMed Web of Science ®Google Scholar
• AhnenDJFeiglPQuanGK-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer. A Southwest Oncology Group StudyCancer Res199858114911589515799
   PubMed Web of Science ®Google Scholar
• LievreABachetJBBoigeVKRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol20082637437918202412
   PubMed Web of Science ®Google Scholar
• RakJYuJLKerbelRSCoomberBLWhat do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?Cancer Res2006621931193411929804
   PubMed Web of Science ®Google Scholar
• MizukamiYKohgoYChungDCHypoxia inducible factor-1 independent pathways in tumor angiogenesisClin Cancer Res2007135670567417908955
   PubMed Web of Science ®Google Scholar
• HurwitzHIYiJInceWNovotnyWFRosenOThe clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancerOncologist200914222819144677
   PubMed Web of Science ®Google Scholar
• PriceTJHardinghamJELeeCKImpact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancerJ Clin Oncol2011292675268221646616
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab and cetuximab in metastatic colorectal cancerN Engl J Med200936056357019196673
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTA randomized Phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Clin Oncol20092767268019114685
   PubMed Web of Science ®Google Scholar
• CiardielloFBiancoRDamianoVAntiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cellsClin Cancer Res200063739374710999768
   PubMed Web of Science ®Google Scholar
• ShaheenRMAhmadSALiuWInhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptorsBr J Cancer20018558458911506500
   PubMed Web of Science ®Google Scholar
• SaltzLBLenzHJKindlerHLRandomized Phase II trial of cetuximab, bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 studyJ Clin Oncol2007254557456117876013
   PubMed Web of Science ®Google Scholar
• KozloffMFSugrueMPurdieDMSafety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from BRiTE observational cohort studyJ Clin Oncol20082615SAbstract 4026
   Google Scholar
• CassidyJSaltzLBGiantonioBJKabbinavarFFHurwitzHIRohrUPEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJ Cancer Res Clin Oncol201013673774319904559
   PubMed Web of Science ®Google Scholar
• KabbinavarFHurwitzHIYiJSarkarSRosenOAddition of bevacizumab to fluorouracil based line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized trialsJ Clin Oncol20092719920519064978
   PubMed Web of Science ®Google Scholar
• ScogginsCRCampbellMLLandryCSPreoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastasesAnn Surg Oncol200916354118987915
   PubMed Web of Science ®Google Scholar
• ReddySKMorseMAHurwitzHIAddition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastasesJ Am Coll Surg20082069610618155574
   PubMed Web of Science ®Google Scholar
• ChongGCunninghamDImproving long-term outcomes for patients with liver metastases from colorectal cancerJ Clin Oncol2005239063906616301589
   PubMed Web of Science ®Google Scholar
• KlingerMEipeldauerSHackerBBevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastasesEur J Surg Oncol20093551552019200687
   PubMed Web of Science ®Google Scholar
• GruenbergerBScheithauerWPunzengruberRZielinskiCTamandlDGruenbergerTImportance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastasesBMC Cancer2008812018439246
   PubMed Web of Science ®Google Scholar